Shakeela Bahadur, MD, specialist, Breast Medical Oncology, Medical Oncology, Banner MD Anderson Cancer Center, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Palbociclib (Ibrance) was the first CDK4/6 inhibitor to gain accelerated approval by the FDA for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer in 2015, Bahadur begins. This regulatory decision was soon followed by approvals for ribociclib (Kisqali) and abemaciclib (Verzenio) in this space.

Accordingly, palbociclib was a commonly selected treatment option in the first line, Bahadur explains. However, findings from the phase 3 PALOMA-2 trial (NCT01740427) showed that the agent in combination with letrozole (Femara) did not provide a statistically and clinically significant overall survival (OS) benefit vs letrozole alone for postmenopausal patients, Bahadur states.

Conversely, ribociclib was shown to improve OS and progression-free survival in both the phase 3 MONALEESA-2 (NCT01958021) and the MONALEESA-3 (NCT02422615) trials when added to first-line ovarian function suppression, she continues. Interim findings from the phase 3 MONARCH-2 trial (NCT02107703) also demonstrated a positive OS trend with abemaciclib in combination with fulvestrant (Faslodex), Bahadur shares.

These data support ribociclib and potentially abemaciclib as a preferred option for patients with advanced or metastatic breast cancer in the first line over palbociclib. However, palbociclib can still have a role in this setting, depending on whether patients have comorbid conditions and may not respond favorably to ribociclib, Bahadur concludes. 

Videos

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Shakeela Bahadur, MD

Articles

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer